Navigation Links
Pluristem to Present Two Scientific Posters at the International,Society for Cellular Therapy

ose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

Contact

Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
or
Strategic Growth International, Inc.
Richard Cooper, 212-838-1444
rcooper@sgi-ir.com
Miri Segal, 212-838-1444
msegal@sgi-ir.com
Jennifer Zimmons, 212-838-1444
jzimmons@sgi-ir.com
or
Segue Ventures LLC
Craig Bird, 215-885â??4981
CHBird@segue.biz
or
Investorsâ?? Message Board:
http://finance.groups.yahoo.com/group/Pluristem_IR/


'"/>




Page: 1 2 3

Related medicine technology :

1. Pluristems PLX Cells Demonstrate Potential to Treat Parkinsons Disease
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:6/30/2015)... ATLANTA , June 30, 2015 Legal-Bay ... the first bellwether trial in the multidistrict litigation (MDL) ... scheduled to begin October 13 th , 2015. There ... Inc. which have been consolidated before a federal judge ... that the first bellwether trial will begin in October ...
(Date:6/29/2015)... , June 29, 2015  Daktari Diagnostics was honored at ... Technology in the Service of Society Award. IEEE President and ... Barry L. Shoop presented the award to Principal Scientist ... ceremony was held Saturday, June 20, 2015, at the historic ... . "I have spent more than 3 ...
(Date:6/29/2015)... Minn. , June 29, 2015 EnteroMedics ... of devices that use neuroblocking technology to treat obesity, ... it has commenced an underwritten public offering of units. ... stock, Series A warrants to purchase common stock and ... purchase of units in the offering would result in ...
Breaking Medicine Technology:Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 2Legal-Bay Lawsuit Settlement Funding Reports Zimmer NexGen Knee Bellwether Trial to Begin October 13th, 2015 3Daktari Honored with IEEE Spectrum Award 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Proposed Public Offering of Common Stock and Warrants 3
... 5 P.M. EDT MONDAY, AUG. 4/, /ADVANCE/ ROCKVILLE, ... should not be,screened for prostate cancer, and younger men ... (PSA) test with their clinicians,before being tested, according to ... The recommendation and accompanying,evidence summary appear in the August ...
... 12 with 48-week boceprevir-based ... combination therapy ... KENILWORTH, N.J., Aug. 4 Schering-Plough,Corporation (NYSE: SGP ) today reported ... boceprevir, its investigational,oral hepatitis C protease inhibitor. The analysis showed a high ...
Cached Medicine Technology:Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer 2Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 2Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 3Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 4Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 5Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 6Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 7Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 8Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients 9
(Date:6/30/2015)... ... ... Trenton Health Team has been certified by the New Jersey Department of Human ... serving the greater Trenton community. The ACO pilot is for a three-year period, ... structure of THT, bringing together the vast majority of Trenton’s primary and specialty care ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... Pharmacy’s premier event and tradeshow, taking place July 29 to August 1. Retail ... makers. , ThoughtSpot is a four-day event for independent community pharmacies, ...
(Date:6/30/2015)... ... 30, 2015 , ... The American Lung Association in California announced its new ... Diego. Speakers and clean air advocates included San Diego County Supervisor Ron Roberts, Dr. ... and Daniel Sullivan, founder and president of Sullivan Solar Power. , For every ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... titled, “University Post-Acute Rehab”. The video focuses on the rehab center’s patients and ... indicating it provides the best quality of services available. Each patient attests to ...
(Date:6/30/2015)... ... ... According to a June 15th report from USC News, a ... can be used to “decrease children’s anxiety and negative responses during oral care.” The ... patient experience in a “typical dental environment” with one that provides “visual, auditory and ...
Breaking Medicine News(10 mins):Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 2Health News:Trenton Health Team Certified as Medicaid Accountable Care Organization 3Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 2Health News:Retail Management Solutions to Attend Amerisource's ThoughtSpot 2015 Conference and Trade Show 3Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 2Health News:Local Dignitaries Gather to Announce San Diego’s Clean Air Challenge 3Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3
... June 6 (HealthDay News) -- Men who have type 2 ... from a regular exercise regimen, a new study has found. ... boost survival rates for men with both conditions, researchers found. ... which commonly occurs in people with diabetes and high blood ...
... A new poll by the Harvard School of Public Health ... the health care reform legislation enacted in 2006, 21% oppose ... heard or read about the law. The percentage of residents ... Support for the law varied by party affiliation, with 77% ...
... Hull have discovered a way to load up nanoparticles ... more effective form of photodynamic therapy (PDT) for treating ... light, cause irreparable damage to cells by creating toxic ... works with individual light-sensitive molecules but the new ...
... CHICAGO As the world marks the 30-year anniversary of ... a new challenge for people with the incurable disease. ... higher rate of cancers not usually associated with HIV. ... and neck, liver, kidney, and anal cancers, among others. ...
... A new targeted therapy for prostate cancer halts tumor ... resistant to hormone therapy, a new study finds. The ... 93rd Annual Meeting in Boston. "This targeted therapy ... lives of men with advanced, hormone-refractory prostate cancer," said ...
... Amanda Gardner HealthDay Reporter , SATURDAY, June 4 ... cancer drug, Avastin, may benefit both early stage ovarian cancer ... both studies, presented Saturday at the annual meeting of the ... added to standard chemotherapy. But the high cost ...
Cached Medicine News:Health News:Exercise Helps Men Battling Diabetes and Sleep Apnea 2Health News:Support for Massachusetts landmark health reform law rises in 2011 2Health News:Support for Massachusetts landmark health reform law rises in 2011 3Health News:Research creates nanoparticles perfectly formed to tackle cancer 2Health News:Many of those living with HIV face a new life-threatening challenge: cancer 2Health News:Many of those living with HIV face a new life-threatening challenge: cancer 3Health News:Targeted cancer therapy kills prostate tumor cells 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 2Health News:Cancer Drug Avastin Makes Inroads Against Ovarian Tumors 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: